financetom
Business
financetom
/
Business
/
Darden Restaurants Likely to Post 'Strong' Q4 Amid Improved Casual Dining Trends, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Darden Restaurants Likely to Post 'Strong' Q4 Amid Improved Casual Dining Trends, Morgan Stanley Says
Jun 18, 2025 8:45 AM

11:19 AM EDT, 06/18/2025 (MT Newswires) -- Darden Restaurants ( DRI ) is likely to post "strong" Q4 results amid an improvement in the casual dining sector, Morgan Stanley said in an earnings preview report Wednesday.

Relatively strong casual dining trends could be attributed to demographic exposure, value proposition, and "ongoing bankruptcies helping the better-off," Morgan Stanley analysts said. While casual dining is still cyclical, some brands, including Olive Garden ( DRI ), held up well in past cycles, according to the brokerage.

Olive Garden ( DRI ) could be benefitting from delivery, enhanced marketing, product innovation, and easy compares, Morgan Stanley analysts said.

For fiscal 2026, the brokerage said it is modeling EPS of $10.78 compared with $10.64 earlier and a 2.8% growth in same-restaurant-sales, which could be beatable if current tailwinds in casual dining and delivery trends persist, according to the note.

The brokerage said it is modeling Q4 blended same-restaurant sales of 3.9% compared with a prior view of 3.7% growth. It also modeled same-restaurant sales estimates for Oliver Garden and LongHorn Steakhouse at 5.3% and 5.6%, respectively, versus 4.6% and 6.3% earlier.

Morgan Stanley reiterated its overweight rating on the stock and lifted its price target to $235 per share from $215.

Price: 223.33, Change: -1.45, Percent Change: -0.65

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Rexford Industrial Realty Insider Sold Shares Worth $1,483,343, According to a Recent SEC Filing
Rexford Industrial Realty Insider Sold Shares Worth $1,483,343, According to a Recent SEC Filing
Jul 29, 2024
03:56 AM EDT, 07/29/2024 (MT Newswires) -- Howard Schwimmer, Director, Co-Chief Executive Officer, Co-President, on July 24, 2024, sold 30,358 shares in Rexford Industrial Realty ( REXR ) for $1,483,343. Following the Form 4 filing with the SEC, Schwimmer has control over a total of 64,248 shares of the company, with 50,673 shares held directly and 13,575 controlled indirectly. SEC...
Moderna Insider Sold Shares Worth $1,766,972, According to a Recent SEC Filing
Moderna Insider Sold Shares Worth $1,766,972, According to a Recent SEC Filing
Jul 29, 2024
03:56 AM EDT, 07/29/2024 (MT Newswires) -- Noubar Afeyan, Director, on July 24, 2024, sold 15,000 shares in Moderna ( MRNA ) for $1,766,972. Following the Form 4 filing with the SEC, Afeyan has control over a total of 6,871,164 shares of the company, with 2,239,015 shares held directly and 4,632,149 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1682852/000095017024087026/xslF345X03/ownership.xml Price: 121.39, Change: -0.72,...
Argan Insider Sold Shares Worth $1,177,274, According to a Recent SEC Filing
Argan Insider Sold Shares Worth $1,177,274, According to a Recent SEC Filing
Jul 29, 2024
03:54 AM EDT, 07/29/2024 (MT Newswires) -- David Hibbert Watson, Director, President and Chief Executive Officer, on July 24, 2024, sold 15,134 shares in Argan (AGX) for $1,177,274. Following the Form 4 filing with the SEC, Watson has control over a total of 44,348 shares of the company, with 44,348 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/100591/000141588924020157/xslF345X03/form4-07262024_040704.xml Price: 78.79, Change: +1.20,...
GSK settles another heartburn drug lawsuit in Illinois
GSK settles another heartburn drug lawsuit in Illinois
Jul 29, 2024
July 29 (Reuters) - British drugmaker GSK said on Monday it has agreed to confidentially settle a lawsuit in Illinois that alleged its discontinued heartburn drug Zantac caused cancer, the latest in a series of settlements to end costly litigation. First approved in 1983, Zantac, sold at different times by GSK, Pfizer ( PFE ) , Sanofi and Boehringer Ingelheim,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved